Baminercept  (Synonyms: BG 9924; TT-47)

Baminercept (BG 9924) is an anti-lymphotoxin β receptor (LTβR) IgG fusion protein (LTβR-Ig). Baminercept selectively binds to the LTβR ligand LTα/β heterotrimer and LIGHT, block the LTβR signaling pathway, and inhibits the expression of chemokines such as CXCL13. Baminercept also regulates peripheral blood B cell and T cell subsets, reduces the transcription of IFN-induced genes. Thereby, Baminercept inhibits the formation of high endothelial venules and reticular structures in lymphoid tissues, and affects immune cell migration. Baminercept can be used for the study of autoimmune diseases such as primary Sjogren's syndrome (pSS) and rheumatoid arthritis (RA)^[1][2].

909110-25-4

Liquid

Colorless to light yellow

[Baminercept]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  [LTBR (lymphotoxin beta receptor, TNFRSF3, tumor necrosis factor receptor superfamily (TNFR)member 3, TNFCR)]2-IGHG1 Fc (Fragment constant)

• 
  Immobilized TNF-beta/TNFSF1 Protein, Human (HY-P7304) can bind Baminercept. The EC₅₀ for this effect is 16.53 ng/mL.

• [1]. E William St Clair, et al. Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2018 Sep;70(9):1470-1480.  [Content Brief]

  [2]. Jadwiga Bienkowska, et al. Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis. PLoS One. 2014 Nov 18;9(11):e112545.  [Content Brief]